- Home
- XOMAP vs BBU Comparison
XOMAP vs BBU Comparison
Compare XOMAP & BBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- BBU
- Stock Information
- Founded
- XOMAP N/A
- BBU 2016
- Country
- XOMAP United States
- BBU Bermuda
- Employees
- XOMAP 13
- BBU N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- BBU Engineering & Construction
- Sector
- XOMAP Health Care
- BBU Consumer Discretionary
- Exchange
- XOMAP Nasdaq
- BBU Nasdaq
- Market Cap
- XOMAP N/A
- BBU N/A
- IPO Year
- XOMAP N/A
- BBU N/A
- Fundamental
- Price
- XOMAP $25.62
- BBU $24.59
- Analyst Decision
- XOMAP
- BBU Buy
- Analyst Count
- XOMAP 0
- BBU 4
- Target Price
- XOMAP N/A
- BBU $32.25
- AVG Volume (30 Days)
- XOMAP N/A
- BBU 17.4K
- Earning Date
- XOMAP N/A
- BBU 01-31-2025
- Dividend Yield
- XOMAP N/A
- BBU 1.02%
- EPS Growth
- XOMAP N/A
- BBU N/A
- EPS
- XOMAP N/A
- BBU N/A
- Revenue
- XOMAP N/A
- BBU $40,620,000,000.00
- Revenue This Year
- XOMAP N/A
- BBU $2.73
- Revenue Next Year
- XOMAP N/A
- BBU N/A
- P/E Ratio
- XOMAP N/A
- BBU N/A
- Revenue Growth
- XOMAP N/A
- BBU N/A
- 52 Week Low
- XOMAP N/A
- BBU $16.85
- 52 Week High
- XOMAP N/A
- BBU $26.75
- Technical
- Relative Strength Index (RSI)
- XOMAP 47.68
- BBU 61.70
- Support Level
- XOMAP $25.57
- BBU $24.68
- Resistance Level
- XOMAP $25.83
- BBU $25.46
- Average True Range (ATR)
- XOMAP 0.11
- BBU 0.75
- MACD
- XOMAP -0.01
- BBU 0.29
- Stochastic Oscillator
- XOMAP 24.24
- BBU 80.80
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.